We are also advancing a number of other small molecule development programs, including a CDK12 inhibitor. CDK12 is an essential regulator of DNA damage response genes against which no targeted therapies are currently approved or, to our knowledge, in clinical development. We expect to develop a CDK12 candidate to target the treatment of ovarian carcinoma (OC), triple-negative breast cancer (TNBC), and metastatic castration-resistant prostate cancer (mCRPC). CDK12 along with our other small molecule development programs expand our penetration into cancer types not covered by existing targeted therapies.